Ablation of N-terminal ITAMS in CARs with CD28 costimulatory domain (XX3) had led to diminished anti-tumor efficacy, whereas CAR-T cells with C-terminal mutated tyrosine residues (1XX) outperformed the CARs without mutation. This evidence concerns the gene CD28 and neoplasm.